Herpes Zoster en Pacientes con Artritis Inflamatorias o Colitis Ulcerosa Tratados con Tofacitinib, Baricitinib o Upadacitinib: Una Revisión Sistemática de Estudios Clínicos y Estudios de Mundo Real
Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.
Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.